Aiforia Technologies Plc Publishes its Board of Directors’ Report and Financial Statements for 2025
Idag, 15:00
Idag, 15:00
Aiforia Technologies Plc, Company release, March 11, 2026 at 16:00 EET
Aiforia Technologies Plc Publishes its Board of Directors’ Report and Financial Statements for 2025
Aiforia Technologies Plc’s Board of Directors’ Report and Financial Statements for 2025 have been published. The Financial Statements consist of the consolidated as well as the parent company’s financial statements and auditor’s report.
The Board of Director’s Report and Financial Statements can be found attached to this release and are also available on the company’s website as pdf files in Finnish and English at https://investors.aiforia.com/en/reports_and_presentations.
Aiforia Technologies Plc
Board of Directors
Further inquiries
Jukka Tapaninen, CEO, Aiforia Technologies Plc
tel. +33 61 041 6686
https://investors.aiforia.com/
Certified Adviser
UB Corporate Finance Ltd
ubcf@unitedbankers.fi
About Aiforia
Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers advanced software solutions that elevate diagnostic capabilities in image analysis, empowering remarkable medical discoveries both today and in the future. With thousands of AI models developed for research use and several diagnostic solutions deployed, Aiforia is making a significant impact on pathology and healthcare. In Europe, Aiforia is the leading provider of CE-IVD marked AI-powered solutions for digital pathology.
Founded in 2013, Aiforia is a publicly traded company with a global presence and thousands of users worldwide. Headquartered in Helsinki, Finland, the company also operates subsidiaries in the United States and France, and maintains a network of local representatives across Europe and North America. Aiforia’s diverse team includes experienced AI and software developers, pathologists, medical scientists, and a dedicated commercial team. Together, they are transforming pathology through AI, enabling better care for every patient.
Find out more at www.aiforia.com
AttachmentsAiforia Board of Directors’ Report and Financial Statements 2025.pdf
Idag, 15:00
Aiforia Technologies Plc, Company release, March 11, 2026 at 16:00 EET
Aiforia Technologies Plc Publishes its Board of Directors’ Report and Financial Statements for 2025
Aiforia Technologies Plc’s Board of Directors’ Report and Financial Statements for 2025 have been published. The Financial Statements consist of the consolidated as well as the parent company’s financial statements and auditor’s report.
The Board of Director’s Report and Financial Statements can be found attached to this release and are also available on the company’s website as pdf files in Finnish and English at https://investors.aiforia.com/en/reports_and_presentations.
Aiforia Technologies Plc
Board of Directors
Further inquiries
Jukka Tapaninen, CEO, Aiforia Technologies Plc
tel. +33 61 041 6686
https://investors.aiforia.com/
Certified Adviser
UB Corporate Finance Ltd
ubcf@unitedbankers.fi
About Aiforia
Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers advanced software solutions that elevate diagnostic capabilities in image analysis, empowering remarkable medical discoveries both today and in the future. With thousands of AI models developed for research use and several diagnostic solutions deployed, Aiforia is making a significant impact on pathology and healthcare. In Europe, Aiforia is the leading provider of CE-IVD marked AI-powered solutions for digital pathology.
Founded in 2013, Aiforia is a publicly traded company with a global presence and thousands of users worldwide. Headquartered in Helsinki, Finland, the company also operates subsidiaries in the United States and France, and maintains a network of local representatives across Europe and North America. Aiforia’s diverse team includes experienced AI and software developers, pathologists, medical scientists, and a dedicated commercial team. Together, they are transforming pathology through AI, enabling better care for every patient.
Find out more at www.aiforia.com
AttachmentsAiforia Board of Directors’ Report and Financial Statements 2025.pdf
Oljepriset
Analyser
Clas Ohlson
Kritiken mot Kinnevik
Oljepriset
Analyser
Clas Ohlson
Kritiken mot Kinnevik
1 DAG %
Senast
OMX Stockholm 30
−0,63%
(16:33)
OMX Stockholm 30
1 DAG %
Senast
3 063,08